Lactoferrin Adsorbed onto Biomimetic Hydroxyapatite Nanocrystals Controlling - In Vivo - the Helicobacter pylori Infection

The resistance of Helicobacter pylori to the antibiotic therapy poses the problem to discover new therapeutic approaches. Recently it has been stated that antibacterial, immunomodulatory, and antioxidant properties of lactoferrin are increased when this protein is surface-linked to biomimetic hydrox...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 7; p. e0158646
Main Authors Fulgione, Andrea, Nocerino, Nunzia, Iannaccone, Marco, Roperto, Sante, Capuano, Federico, Roveri, Norberto, Lelli, Marco, Crasto, Antonio, Calogero, Armando, Pilloni, Argenia Paola, Capparelli, Rosanna
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 06.07.2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The resistance of Helicobacter pylori to the antibiotic therapy poses the problem to discover new therapeutic approaches. Recently it has been stated that antibacterial, immunomodulatory, and antioxidant properties of lactoferrin are increased when this protein is surface-linked to biomimetic hydroxyapatite nanocrystals. Based on these knowledge, the aim of the study was to investigate the efficacy of lactoferrin delivered by biomimetic hydroxyapatite nanoparticles with cell free supernatant from probiotic Lactobacillus paracasei as an alternative therapy against Helicobacter pylori infection. Antibacterial and antinflammatory properties, humoral antibody induction, histopathological analysis and absence of side effects were evaluated in both in vitro and in vivo studies. The tests carried out have been demonstrated better performance of lactoferrin delivered by biomimetic hydroxyapatite nanoparticles combined with cell free supernatant from probiotic Lactobacillus paracasei compared to both lactoferrin and probiotic alone or pooled. These findings indicate the effectiveness and safety of our proposed therapy as alternative treatment for Helicobacter pylori infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: RC. Performed the experiments: AF NN MI SR ML A. Calogero APP. Analyzed the data: AF NN MI SR FC NR ML RC A. Crasto. Contributed reagents/materials/analysis tools: NR ML FC RC. Wrote the paper: RC.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0158646